Mexican health regulator COFEPRIS approves the emergency use of Eli Lilly and Company's injectable combination of bamlanivimab and etesevimab to treat mild to moderate…
Mexican health regulator COFEPRIS approves the emergency use of Eli Lilly and Company's injectable combination of bamlanivimab and etesevimab to treat mild to moderate COVID-19 cases in people over the age of 12 years who weigh at least .
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthMexican health regulator COFEPRIS approves the emergency use of Eli Lilly and Company's injectable combination of bamlanivimab and etesevimab to treat mild to moderate…
View Premium plansBrowse free archive reportsMexican health regulator COFEPRIS approves the emergency use of Eli Lilly and Company's injectable combination of bamlanivimab and etesevimab to treat mild to moderate COVID-19 cases in people over the age of 12 years who weigh at least .